Lymphoma of the nasal cavity and paranasal sinuses: A case series

Toby Steele, Maria C. Buniel, Jess C. Mace, Edward El Rassi, Timothy Smith

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Lymphomas of the sinonasal tract are a rare and heterogeneous subset of solid sinonasal neoplasms. Objective: To characterize, in this case series, presenting symptoms, treatment modalities, and outcomes for patients with sinonas ymphoma with n a single institution. Methods: Retrospective patient data were collected from an academic, oncologic center and entered into a repository designed to capture outcomes for sinonasal malignancies. Patient demographics, presenting symptoms, imaging findings, treatment modalities, and health status were retrospectively extrapolated and evaluated by using Kaplan-Meier estimations for survival probability. Results: Patients with sinonasal lymphoma with a mean follow-up of 50 months were identified (n =). Histologic nosis included the following: diffuse large B-cell lymphoma (n = 9), natural killer/T-cell lymphoma (n = 5), follicular lymphoma (n = 1), T-cell lymphoma (n = 1), and lymphoma-not otherwise specified (n = 2). The most frequent presenting symptoms were nasal obstruction (78%), facial pain (72%), al swelling (50%), and nasal discharge (44%). Treatment before lymphoma diagnosis included antibiotics (83%), oral steroids (22%), decongestants (22%), and topical steroids (11%). Treatment regimens after diagnosis included both chemotherapy (94%) and chemoradiotherapy (56%). Survival rates by lymphoma subtype were 56% for B-cell lymphoma and 40% for natural killer/T-cell lymphoma. Overall, 2- and 5-year survival rates were 67% and 50%, respectively. The combination of chemotherapy and radiation resulted in significantly higher survival rates (p ≥ 0.001) than emotherapy ne. Conclusion: Sinonasal lymphomas are characterized by meager survival rates, which differ by histopathologic subtype. The diagnosis of sinonasal lymphoma is challenging because symptoms frequently parallel those of chronic rhinosinusitis. Increased awareness of these rare malignancies may improve detection and more timely treatment. Clinical trial registration NCT01332136.

Original languageEnglish (US)
Pages (from-to)335-339
Number of pages5
JournalAmerican Journal of Rhinology and Allergy
Volume30
Issue number5
DOIs
StatePublished - Sep 1 2016

Fingerprint

Paranasal Sinuses
Nasal Cavity
Lymphoma
T-Cell Lymphoma
Survival Rate
Natural Killer T-Cells
Steroids
Nasal Decongestants
Neoplasms
Facial Pain
Nasal Obstruction
Follicular Lymphoma
Lymphoma, Large B-Cell, Diffuse
Chemoradiotherapy
B-Cell Lymphoma
Therapeutics
Combination Drug Therapy
Nose
Health Status
Demography

ASJC Scopus subject areas

  • Immunology and Allergy
  • Otorhinolaryngology

Cite this

Lymphoma of the nasal cavity and paranasal sinuses : A case series. / Steele, Toby; Buniel, Maria C.; Mace, Jess C.; Rassi, Edward El; Smith, Timothy.

In: American Journal of Rhinology and Allergy, Vol. 30, No. 5, 01.09.2016, p. 335-339.

Research output: Contribution to journalArticle

Steele, Toby ; Buniel, Maria C. ; Mace, Jess C. ; Rassi, Edward El ; Smith, Timothy. / Lymphoma of the nasal cavity and paranasal sinuses : A case series. In: American Journal of Rhinology and Allergy. 2016 ; Vol. 30, No. 5. pp. 335-339.
@article{16b9ded4860c48cbaba9444324b357e9,
title = "Lymphoma of the nasal cavity and paranasal sinuses: A case series",
abstract = "Background: Lymphomas of the sinonasal tract are a rare and heterogeneous subset of solid sinonasal neoplasms. Objective: To characterize, in this case series, presenting symptoms, treatment modalities, and outcomes for patients with sinonas ymphoma with n a single institution. Methods: Retrospective patient data were collected from an academic, oncologic center and entered into a repository designed to capture outcomes for sinonasal malignancies. Patient demographics, presenting symptoms, imaging findings, treatment modalities, and health status were retrospectively extrapolated and evaluated by using Kaplan-Meier estimations for survival probability. Results: Patients with sinonasal lymphoma with a mean follow-up of 50 months were identified (n =). Histologic nosis included the following: diffuse large B-cell lymphoma (n = 9), natural killer/T-cell lymphoma (n = 5), follicular lymphoma (n = 1), T-cell lymphoma (n = 1), and lymphoma-not otherwise specified (n = 2). The most frequent presenting symptoms were nasal obstruction (78{\%}), facial pain (72{\%}), al swelling (50{\%}), and nasal discharge (44{\%}). Treatment before lymphoma diagnosis included antibiotics (83{\%}), oral steroids (22{\%}), decongestants (22{\%}), and topical steroids (11{\%}). Treatment regimens after diagnosis included both chemotherapy (94{\%}) and chemoradiotherapy (56{\%}). Survival rates by lymphoma subtype were 56{\%} for B-cell lymphoma and 40{\%} for natural killer/T-cell lymphoma. Overall, 2- and 5-year survival rates were 67{\%} and 50{\%}, respectively. The combination of chemotherapy and radiation resulted in significantly higher survival rates (p ≥ 0.001) than emotherapy ne. Conclusion: Sinonasal lymphomas are characterized by meager survival rates, which differ by histopathologic subtype. The diagnosis of sinonasal lymphoma is challenging because symptoms frequently parallel those of chronic rhinosinusitis. Increased awareness of these rare malignancies may improve detection and more timely treatment. Clinical trial registration NCT01332136.",
author = "Toby Steele and Buniel, {Maria C.} and Mace, {Jess C.} and Rassi, {Edward El} and Timothy Smith",
year = "2016",
month = "9",
day = "1",
doi = "10.2500/ajra.2016.30.4347",
language = "English (US)",
volume = "30",
pages = "335--339",
journal = "American Journal of Rhinology and Allergy",
issn = "1945-8924",
publisher = "OceanSide Publications Inc.",
number = "5",

}

TY - JOUR

T1 - Lymphoma of the nasal cavity and paranasal sinuses

T2 - A case series

AU - Steele, Toby

AU - Buniel, Maria C.

AU - Mace, Jess C.

AU - Rassi, Edward El

AU - Smith, Timothy

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Background: Lymphomas of the sinonasal tract are a rare and heterogeneous subset of solid sinonasal neoplasms. Objective: To characterize, in this case series, presenting symptoms, treatment modalities, and outcomes for patients with sinonas ymphoma with n a single institution. Methods: Retrospective patient data were collected from an academic, oncologic center and entered into a repository designed to capture outcomes for sinonasal malignancies. Patient demographics, presenting symptoms, imaging findings, treatment modalities, and health status were retrospectively extrapolated and evaluated by using Kaplan-Meier estimations for survival probability. Results: Patients with sinonasal lymphoma with a mean follow-up of 50 months were identified (n =). Histologic nosis included the following: diffuse large B-cell lymphoma (n = 9), natural killer/T-cell lymphoma (n = 5), follicular lymphoma (n = 1), T-cell lymphoma (n = 1), and lymphoma-not otherwise specified (n = 2). The most frequent presenting symptoms were nasal obstruction (78%), facial pain (72%), al swelling (50%), and nasal discharge (44%). Treatment before lymphoma diagnosis included antibiotics (83%), oral steroids (22%), decongestants (22%), and topical steroids (11%). Treatment regimens after diagnosis included both chemotherapy (94%) and chemoradiotherapy (56%). Survival rates by lymphoma subtype were 56% for B-cell lymphoma and 40% for natural killer/T-cell lymphoma. Overall, 2- and 5-year survival rates were 67% and 50%, respectively. The combination of chemotherapy and radiation resulted in significantly higher survival rates (p ≥ 0.001) than emotherapy ne. Conclusion: Sinonasal lymphomas are characterized by meager survival rates, which differ by histopathologic subtype. The diagnosis of sinonasal lymphoma is challenging because symptoms frequently parallel those of chronic rhinosinusitis. Increased awareness of these rare malignancies may improve detection and more timely treatment. Clinical trial registration NCT01332136.

AB - Background: Lymphomas of the sinonasal tract are a rare and heterogeneous subset of solid sinonasal neoplasms. Objective: To characterize, in this case series, presenting symptoms, treatment modalities, and outcomes for patients with sinonas ymphoma with n a single institution. Methods: Retrospective patient data were collected from an academic, oncologic center and entered into a repository designed to capture outcomes for sinonasal malignancies. Patient demographics, presenting symptoms, imaging findings, treatment modalities, and health status were retrospectively extrapolated and evaluated by using Kaplan-Meier estimations for survival probability. Results: Patients with sinonasal lymphoma with a mean follow-up of 50 months were identified (n =). Histologic nosis included the following: diffuse large B-cell lymphoma (n = 9), natural killer/T-cell lymphoma (n = 5), follicular lymphoma (n = 1), T-cell lymphoma (n = 1), and lymphoma-not otherwise specified (n = 2). The most frequent presenting symptoms were nasal obstruction (78%), facial pain (72%), al swelling (50%), and nasal discharge (44%). Treatment before lymphoma diagnosis included antibiotics (83%), oral steroids (22%), decongestants (22%), and topical steroids (11%). Treatment regimens after diagnosis included both chemotherapy (94%) and chemoradiotherapy (56%). Survival rates by lymphoma subtype were 56% for B-cell lymphoma and 40% for natural killer/T-cell lymphoma. Overall, 2- and 5-year survival rates were 67% and 50%, respectively. The combination of chemotherapy and radiation resulted in significantly higher survival rates (p ≥ 0.001) than emotherapy ne. Conclusion: Sinonasal lymphomas are characterized by meager survival rates, which differ by histopathologic subtype. The diagnosis of sinonasal lymphoma is challenging because symptoms frequently parallel those of chronic rhinosinusitis. Increased awareness of these rare malignancies may improve detection and more timely treatment. Clinical trial registration NCT01332136.

UR - http://www.scopus.com/inward/record.url?scp=84986883245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84986883245&partnerID=8YFLogxK

U2 - 10.2500/ajra.2016.30.4347

DO - 10.2500/ajra.2016.30.4347

M3 - Article

C2 - 27657899

AN - SCOPUS:84986883245

VL - 30

SP - 335

EP - 339

JO - American Journal of Rhinology and Allergy

JF - American Journal of Rhinology and Allergy

SN - 1945-8924

IS - 5

ER -